<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753398</url>
  </required_header>
  <id_info>
    <org_study_id>13/085U</org_study_id>
    <nct_id>NCT04753398</nct_id>
  </id_info>
  <brief_title>One Heart to Care for</brief_title>
  <acronym>1H2C4</acronym>
  <official_title>One Heart to Care for, Your Heart to Take Care of.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WGK Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open randomized clinical trial with two study arms. One group, receiving usual&#xD;
      care for heart failure, will be compared to another group, receiving usual care plus active&#xD;
      telemonitoring interference.&#xD;
&#xD;
      When leaving the hospital, the usual care arm receives a document with a predefined&#xD;
      medication scheme and advice for the general practitioner (like it is currently done in usual&#xD;
      care). Besides the normal consultations at 2 and 5 weeks, no active interactions take place&#xD;
      between the study nurse and the patient.&#xD;
&#xD;
      The telemonitoring interference in the other study arm consists of an automatic blood&#xD;
      pressure device and medication dispenser that transmit data to a central platform. During the&#xD;
      first 12 weeks, the nurse of the call center will give incentive for medication up titration&#xD;
      on the basis of the available data. Before up titration can be done, the patient needs to&#xD;
      take blood pressure measurements 3 times in the morning and 3 times in the evening and at&#xD;
      least 6 measurements a week.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients included&#xD;
  </why_stopped>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean medication doses</measure>
    <time_frame>week 12</time_frame>
    <description>Define whether the mean medication doses of angiotensin-converting-enzyme inhibitor (ACE-I) and bètablockers (BB) in the group with telemonitoring is higher than in the group with usual care (without telemonitoring) after 12 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean medication doses</measure>
    <time_frame>week 24</time_frame>
    <description>Define whether the mean medication doses of angiotensin-converting-enzyme inhibitor (ACE-I) and bètablockers (BB) in the group with telemonitoring is higher than in the group with usual care (without telemonitoring) after 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication titration</measure>
    <time_frame>up to one year</time_frame>
    <description>Mean doses ACE-I/angiotensin receptor blockers (ARB) en BB after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to one year</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cardio-related hospitalisations (number and time)</measure>
    <time_frame>Up to one year</time_frame>
    <description>Arrythmogenic nature&#xD;
Ischemic nature&#xD;
Heart failure nature&#xD;
Valvular/surgical nature&#xD;
Elektrofysiological nature (implantation ICD, CRT,…)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All heart failure hospitalisations</measure>
    <time_frame>Up to one year</time_frame>
    <description>Treatment with (whether or not intravenous) diuretic therapy&#xD;
Treatment with hemodynamic guided therapy (vasodilators)&#xD;
Treatment with intravenous inotropics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medical practitioner-patient contacts</measure>
    <time_frame>Up to one year</time_frame>
    <description>In hospital (medical record)&#xD;
At patient home (WGK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of (telephone) contacts, registered by the heart failure nurse</measure>
    <time_frame>Up to one year</time_frame>
    <description>Number of (telephone) contacts, registered by the heart failure nurse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of (telephone) contacts for the encouragement of medication compliance</measure>
    <time_frame>Up to one year</time_frame>
    <description>Number of (telephone) contacts for the encouragement of medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of heart failure and comorbidities</measure>
    <time_frame>up to one year</time_frame>
    <description>Blood collection with: kidney function determinations, electrolytes, heart markers (NT-proBNP)&#xD;
Echo parameters (cardiac output, LVEF, diameters end systolic and diastolic)&#xD;
Exercise stress tests (VO2max, maximal wattage, maximal heart rate)&#xD;
Weight, length, blood pressure, ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life according to the HeartQoL questionnaire</measure>
    <time_frame>day 1, month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction survey</measure>
    <time_frame>month 12</time_frame>
    <description>Satisfaction survey about the received care (anonymous)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Telemonitoring group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional telemonitoring devices: Blood Pressure Monitor, medication dispenser, telemonitoring technology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual care, without telemonitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood Pressure Monitor, medication dispenser, telemonitoring technology</intervention_name>
    <description>The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.</description>
    <arm_group_label>Telemonitoring group</arm_group_label>
    <other_name>Telemedicine</other_name>
    <other_name>remote monitoring</other_name>
    <other_name>remote follow-up</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Age ≥ 50&#xD;
&#xD;
          -  Patient has to be followed in Ziekenhuis Oost-Limburg or Jessa Ziekenhuis Hasselt&#xD;
&#xD;
          -  The patient has to be able to live independently or in a service flat&#xD;
&#xD;
          -  The diagnosis of heart failure or severe myocardial infarction has to be done after&#xD;
             September 1, 2013 according to:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt;40%&#xD;
&#xD;
               -  eGFR&gt;30ml/min/kg&#xD;
&#xD;
               -  Treatment minimally with ACE-I and BB&#xD;
&#xD;
          -  The general practitioner had to give his approval for the installation of&#xD;
             telemonitoring On the basis of an interview between the heart failure nurse and&#xD;
             patient, one will decide if the patient is eligibil to join the study. The patient&#xD;
             also needs to speak sufficient Dutch to be communicative about his/her medical&#xD;
             condition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reversible form of heart failure&#xD;
&#xD;
          -  Heart failure due to severe aortic stenosis&#xD;
&#xD;
          -  eGFR less than 30ml/min/kg&#xD;
&#xD;
          -  Presence of a cardiac resynchronization therapy (CRT) device&#xD;
&#xD;
          -  Palliative status following the RIZIV guidelines or according to the assessment of the&#xD;
             cardiologist (&lt;1 year)&#xD;
&#xD;
          -  Patients staying in a nursing or retirement home&#xD;
&#xD;
          -  Active treatment with either ACE-I/ARB or BB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter Vandervoort, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brenda Aendekerk, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Wit Gele Kruis Limburg, Genk, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valerie Storms, dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Grieten, dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Smeets, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Pieter Vandervoort</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Telemonitoring</keyword>
  <keyword>medication up titration</keyword>
  <keyword>automatic blood pressure device</keyword>
  <keyword>medication dispenser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

